In the closing of the recent trading day, Novavax (NVAX) stood at $6.97, denoting a +1.9% move from the preceding trading day.

Novavax Inc. closed 60.86% short of its 52-week high of $17.81, which the company reached on July 26th.

Novavax Inc. (NASDAQ:NVAX) is one of the best cheap stocks with huge upside potential. On June 11, BTIG maintained a Buy ...

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Methods Randomised, double-blind, multicentre trial of simvastatin versus placebo in patients undergoing elective oesophagectomy, lobectomy or pneumonectomy at 15 sites throughout the UK. Planned ...

Recent developments that have caused concern include removing all members of a scientific committee that advises the Centers for Disease Control and Prevention (CDC) on vaccines and replacing them ...

The government’s top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval ...

The Health and Human Services Department under Kennedy took unprecedented steps to change how vaccines are evaluated, ...

During his Senate confirmation hearings, Health Secretary Robert F. Kennedy Jr. suggested he wouldn’t undermine vaccines. “I am not going to go into HHS and impose my preordained opinions on anybody ...

Although Pfizer's and Moderna’s COVID-19 vaccines have been stealing the spotlight for years, some people are actively seeking out the lesser-known Novavax for their updated booster this fall.

Novavax uses a protein-based vaccine strategy, which means people getting the vaccine receive a protein made by the virus that their body’s immune systems then see as foreign and mount responses ...